New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

Allarity Therapeutics, Inc.

Contributing Author

Recent Articles by Allarity Therapeutics, Inc.

Sep-17	Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 ALLR GlobeNewswire
Aug-26	Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer ALLR GlobeNewswire
Aug-15	Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships ALLR GlobeNewswire
Jul-15	Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP Platform Utilization ALLR GlobeNewswire
Jul-07	Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer ALLR GlobeNewswire
Jun-30	Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP Companion Diagnostic ALLR GlobeNewswire
Jun-27	Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer ALLR GlobeNewswire
Jun-11	Allarity Therapeutics Announces Changes to Board of Directors ALLR GlobeNewswire
Jun-04	Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib's Unique, Dual Therapeutic Mechanism of Action ALLR GlobeNewswire
Jun-02	Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer ALLR GlobeNewswire
May-12	Allarity Therapeutics Announces Participation in Pharma Partnering Summit US ALLR GlobeNewswire
May-09	Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment ALLR GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.